oral anti-obesity agentReviewed for 2026 plan year

Does Anthem Cover Contrave?

The verdict

Conditional on most plans

Anthem covers Contrave only where the plan includes a weight-loss drug benefit. Because Contrave is FDA-approved only for chronic weight management, plans with an anti-obesity carve-out exclude it entirely. Standard Medicare Part D excludes Contrave by statute. Where covered, BMI-based prior authorization applies. For most readers searching 'Anthem Contrave,' the short answer is: check whether your plan covers weight-loss drugs, then consider CurAccess at approximately $99/month if excluded.

MedicareNot Covered
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Anthem using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Anthem drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice
  • Contrave is FDA-approved only for chronic weight management. Any Anthem plan with an anti-obesity carve-out excludes it entirely — check your drug list before filing a PA.

    FDA Prescribing Information, naltrexone/bupropion (Contrave)

  • Medicare Part D excludes weight-loss agents by statute. The manufacturer coupon also excludes Medicare members. CurAccess (~$99/mo) is the cash route for government-insured.

    CMS.gov Medicare Part D statutory exclusions; Currax CurAccess program

  • There is no generic for Contrave. CurAccess at approximately $99/month with free shipping is the main cost-reduction program for patients without coverage.

    Currax Pharmaceuticals CurAccess program

Medicare vs. commercial coverage

Whether Anthem covers Contrave depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Not Covered

Standard Medicare Part D excludes Contrave by federal statute. The 2026 GLP-1 Bridge does not cover Contrave (Bridge covers only Wegovy, Foundayo, Zepbound KwikPen). The manufacturer copay coupon excludes Medicare members. CurAccess (~$99/month cash) is open to government-insured patients who do not bill their plan.

Commercial / Employer

Group & marketplace plans

Conditional

Anthem commercial/employer plans cover Contrave only where the employer group has purchased a weight-loss benefit. ACA/individual Anthem plans often exclude anti-obesity medications. Where covered, BMI-based prior authorization applies: BMI ≥30, or ≥27 with a qualifying comorbidity, plus documented behavioral modification and reduced-calorie diet. Anthem Medicaid (Elevance multi-state) is state-dependent. Cells are composites; verify on Anthem's drug search.

The 4 boxes you must tick to get approved

Commercial plans that will consider Contrave require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 4

0 of 4 requirements selected. Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

Your cost, three ways

What Contrave actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Retail approximately $619 (Drugs.com) to $753 (SingleCare) per month.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Commercial coupon: as low as $0, maximum $199/month without coverage. Usable for Anthem commercial and ACA members; excludes Medicare and Medicaid.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

CurAccess (Currax): approximately $99/month with free shipping. Open to cash-paying patients including government-insured who do not bill their plan. No generic for Contrave.

Reduced copay through the assistance program, where eligible.

All figures are estimates. Confirm with Anthem's drug pricing tool.

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Search your Anthem drug list for Contrave

    Log in at Anthem.com and search for 'Contrave' or 'naltrexone/bupropion.' If the plan has an AOM exclusion, the drug will show as not covered — this is the first and most important check.

  2. 2

    If covered, confirm BMI and behavioral program documentation

    Your BMI (≥30, or ≥27 with a comorbidity) and enrollment in a behavioral/diet program must be documented before your doctor submits the prior authorization to Anthem.

  3. 3

    If excluded, consider CurAccess or the coupon

    CurAccess at approximately $99/month with free shipping is often lower-cost than the commercial coupon's $199/month max without coverage. If you are a commercial/ACA member, compare both. Medicare members: use CurAccess only.

Options if Anthem won't cover Contrave

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

CurAccess (Currax direct program)

Approximately $99/month cash with free shipping — often the fastest, cheapest path for Anthem members whose plan excludes weight-loss drugs.

Qsymia (phentermine/topiramate ER)

Another oral AOM on the same AOM carve-out logic; generic available 2025 (Teva). REMS restrictions and teratogenicity warning apply.

Compounded semaglutide or tirzepatide (via Curex)

Injectable GLP-1-based weight-management option requiring no insurance or prior auth. Not the same medication as Contrave. From $49/month.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

The Curex GLP-1 program

A weight-loss alternative that skips insurance and prior auth

You just saw how tangled Contrave coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Contrave. No insurance or prior authorization required; prescription required, subject to provider review.

Compounded Semaglutide
$299/month
Monthly payment option
$2,388 upfront for one year — equivalent to $199/month
Compounded Tirzepatide
$399/month
Monthly payment option
$3,588 upfront for one year — equivalent to $299/month
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
Monthly or annual paymentNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Contrave and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Anthem before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Contrave and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

A weight-loss alternative that skips insurance and prior auth

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.